Sean Kennelly Selected Research

Cognitive Dysfunction

1/2020	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.
1/2018	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
4/2012	Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sean Kennelly Research Topics

Disease

5	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 04/2012
3	COVID-19 01/2022 - 11/2020
3	Cognitive Dysfunction 01/2020 - 04/2012
3	Dementia (Dementias) 01/2018 - 12/2015
2	Hypertension (High Blood Pressure) 01/2018 - 01/2012
1	Delirium 01/2021
1	Frailty 01/2016
1	Hypoxia (Hypoxemia) 01/2012

Drug/Important Bio-Agent (IBA)

4	nilvadipine (Escor)IBA 01/2020 - 10/2014
3	1,4-dihydropyridine (dihydropyridine)IBA 01/2020 - 04/2012
3	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2020 - 04/2012
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2016
2	Amyloid (Amyloid Fibrils)IBA 01/2018 - 01/2012
2	Apolipoproteins E (ApoE)IBA 01/2016 - 04/2012
1	AutoantibodiesIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2021
1	ApolipoproteinsIBA 01/2016
1	Antipsychotic Agents (Antipsychotics)IBA 12/2015
1	tau Proteins (tau Protein)IBA 01/2012
1	Antihypertensive Agents (Antihypertensives)IBA 01/2012

Therapy/Procedure

1	Home Nursing (Nursing, Home) 11/2020
1	Patient Discharge 01/2016
1	Length of Stay 01/2016
1	Inappropriate Prescribing 12/2015
1	Palliative Care (Palliative Therapy) 12/2015
1	Duration of Therapy 10/2014